Onderzoeksoutput per jaar
Onderzoeksoutput per jaar
Onderzoeksoutput
- 27 resultaten
Zoekresultaten
-
2024
S-adenosylmethionine biosynthesis is a targetable metabolic vulnerability in multiple myeloma
Wang, Y., Muylaert, C., Wyns, A., Vlummens, P., De Veirman, K., Vanderkerken, K., Zaal, E., Berkers, C., Moreaux, J., De Bruyne, E. & Menu, E., 3 jan 2024, In: Haematologica. 109, 1, blz. 256-271 16 blz.Onderzoeksoutput: Article › peer review
Open AccessBestand7 Citaten (Scopus)25 Downloads (Pure) -
2023
Metformin confers sensitisation to syrosingopine in multiple myeloma cells by metabolic blockage and inhibition of protein synthesis
Van der Vreken, A., Oudaert, I., Ates, G., Faict, S., Vlummens, P., Satilmis, H., Fan, R., Maes, A., Massie, A., De Veirman, K., De Bruyne, E., Vanderkerken, K. & Menu, E., 28 mrt 2023, In: Journal of pathology. 260, 2, blz. 112-123 12 blz.Onderzoeksoutput: Article › peer review
Open AccessBestand13 Citaten (Scopus)61 Downloads (Pure) -
Targeting the β2 -adrenergic receptor increases chemosensitivity in multiple myeloma by induction of apoptosis and modulating cancer cell metabolism
Satilmis, H., Verheye, E., Vlummens, P., Oudaert, I., Vandewalle, N., Fan, R., Knight, J. M., De Beule, N., Ates, G., Massie, A., Moreaux, J., Maes, A., De Bruyne, E., Vanderkerken, K., Menu, E., Sloan, E. K. & De Veirman, K., jan 2023, In: Journal of pathology. 259, 1, blz. 69–80 12 blz.Onderzoeksoutput: Article › peer review
Open AccessBestand11 Citaten (Scopus)66 Downloads (Pure) -
Tasquinimod suppresses tumor cell growth and bone resorption by targeting immunosuppressive myeloid cells and inhibiting c-MYC expression in multiple myeloma
Fan, R., Satilmis, H., Vandewalle, N., Verheye, E., Vlummens, P., Maes, A., Muylaert, C., De Bruyne, E., Menu, E., Evans, H., Chantry, A., De Beule, N., Hose, D., Törngren, M., Eriksson, H., Vanderkerken, K., Maes, K., Breckpot, K. & De Veirman, K., 17 jan 2023, In: Journal for ImmunoTherapy Of Cancer. 11, 1, 9 blz., A8.Onderzoeksoutput: Article › peer review
Open AccessBestand7 Citaten (Scopus)35 Downloads (Pure) -
2022
CAMMA 3: A multicenter phase Ib trial evaluating the safety, pharmacokinetics, and activity of subcutaneous cevostamab monotherapy in patients with relapsed or refractory multiple myeloma.
Delimpasi, S., Quach, H., Cavo, M., Ho, P. J., Lee, C., Santoro, A., Schots, R., Vlummens, P., Yoon, D. H., Yoon, S-S., Dos Santos, C., Samineni, D., Huang, J., Wehrman, K., Patil, U., Sheikh, S. & Dimopoulos, M. A., 1 jun 2022, In: Journal of Clinical Oncology. 40, 16, blz. 16-16 1 blz.Onderzoeksoutput: Meeting abstract (Journal)
-
Inhibition of the Protein Arginine Methyltransferase PRMT5 in High-Risk Multiple Myeloma as a Novel Treatment Approach
Vlummens, P., Verhulst, S., De Veirman, K., Maes, A., Menu, E., Moreaux, J., De Bruyne, E., Hose, D., Vanderkerken, K. & Maes, K., 8 jun 2022, In: Frontiers in cell and developmental biology. 10, 11 blz., 879057.Onderzoeksoutput: Article › peer review
Open AccessBestand3 Citaten (Scopus)13 Downloads (Pure) -
Pyrroline-5-Carboxylate Reductase 1: a novel target for sensitizing multiple myeloma cells to bortezomib by inhibition of PRAS40-mediated protein synthesis
Oudaert, I., Satilmis, H., Vlummens, P., De Brouwer, W., Maes, A., Hose, D., De Bruyne, E., Ghesquière, B., Vanderkerken, K., De Veirman, K. & Menu, E., 1 feb 2022, In: Journal of Experimental & Clinical Cancer Research. 41, 1, blz. 45 17 blz., 45.Onderzoeksoutput: Article › peer review
Open AccessBestand23 Citaten (Scopus)61 Downloads (Pure) -
System Xc- inhibition blocks bone marrow-multiple myeloma exosomal crosstalk, thereby countering bortezomib resistance
Wang, F., Oudaert, I., Tu, C., Maes, A., Van der Vreken, A., Vlummens, P., De Bruyne, E., De Veirman, K., Wang, Y., Fan, R., Massie, A., Vanderkerken, K., Shang, P. & Menu, E., jun 2022, In: Cancer Letters. 535, 215649.Onderzoeksoutput: Article › peer review
Open AccessBestand19 Citaten (Scopus)53 Downloads (Pure) -
Targeting of DNMT3B in the plasma cell cancer multiple myeloma disturbs cancer cell growth and clonogenicity and boosts the anti-tumor activity of the proteasome inhibitor bortezomib
Muylaert, C., Van Hemelrijck, L. A., Vlummens, P., Maes, A., De Veirman, K., Menu, E., De Bruyne, E. & Vanderkerken, K., jun 2022.Onderzoeksoutput: Poster
-
Targeting of DNMT3B in the plasma cell cancer multiple myeloma disturbs cancer cell growth and clonogenicity and boosts the anti-tumor activity of the proteasome inhibitor bortezomib.
Muylaert, C., Van Hemelrijck, L. A., Vlummens, P., Maes, A., De Veirman, K., Menu, E., Vanderkerken, K. & De Bruyne, E., 30 sep 2022.Onderzoeksoutput: Poster
-
The de novo DNA methyltransferase DNMT3B plays an important role in multiple myeloma cell growth, clonogenicity and drug response
Muylaert, C., Van Hemelrijck, L. A., Vlummens, P., De Veirman, K., Menu, E., Vanderkerken, K. & De Bruyne, E., 2022.Onderzoeksoutput: Poster
-
2021
Compass: a prospective study comparing clinical evaluation with different geriatric screening methods in newly diagnosed elderly multiple myeloma patients
Delforge, M., Raddoux, J., Kenis, C., Vanhellemont, A., Mineur, P., Hoornaert, E., Wu, K. L., Caers, J., Van Eygen, K., Kentos, A., Depaus, J., Put, N., Van De Velde, A., Claes, G., Vlummens, P., Maertens, V., Meuleman, N., Broek, I. V., Vaes, M., Fostier, K. & 2 anderen, , okt 2021, In: CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 21, blz. S124-S124Onderzoeksoutput: Meeting abstract (Journal)
-
CS1-specific single-domain antibodies labeled with Actinium-225 prolong survival and increase CD8+ T cells and PD-L1 expression in Multiple Myeloma
De Veirman, K., Puttemans, J., Krasniqi, A., Ertveldt, T., Hanssens, H., Romao, E., Hose, D., Goyvaert, C., Vlummens, P., Muyldermans, S., Breckpot, K., Bruchertseifer, F., Morgenstern, A., D'Huyvetter, M. & Devoogdt, N., 2021, In: Oncoimmunology. 10, 1, 11 blz., 2000699.Onderzoeksoutput: Article › peer review
Open AccessBestand15 Citaten (Scopus)32 Downloads (Pure) -
G9a/GLP-targeting in MM promotes autophagy-associated apoptosis and boosts proteasome inhibitor mediated cell death
De Smedt, E., Devin, J., Muylaert, C., Robert, N., Requirand, G., Vlummens, P., Vincent, L., Cartron, G., Maes, K., Moreaux, J. & De Bruyne, E., 24 feb 2021, In: Blood Advances. 5, 9, blz. 2325-2338 14 blz.Onderzoeksoutput: Article › peer review
Open AccessBestand24 Citaten (Scopus)61 Downloads (Pure) -
The therapeutic potential of Actinium-225-labeled CS1-specific single-domain antibodies for the treatment of Multiple Myeloma
De Veirman, K., Puttemans, J., Krasniqi, A., Hanssens, H., Romao, E., Vlummens, P., Breckpot, K., Hose, D., Bruchertseifer, F., Morgenstern, A., D'Huyvetter, M. & Devoogdt, N., 8 sep 2021, blz. 79-79. 1 blz.Onderzoeksoutput: Unpublished abstract
-
2020
AXL: A potential therapeutic target to eliminate cancer cells and improve chemotherapeutic responses in different hematological cancers
Vlummens, P., De Beule, N., Faict, S., Oudaert, I., Maes, K., De Bruyne, E., Menu, E., Vanderkerken, K. & De Veirman, K., 14 feb 2020, In: Belgian Journal of Hematology. 11, O2, blz. 9-9 1 blz., 11.Onderzoeksoutput: Meeting abstract (Journal)
-
2019
Maternal embryonic leucine zipper kinase is a novel target for diffuse large B cell lymphoma and mantle cell lymphoma
Maes, A., Maes, K., Vlummens, P., De Raeve, H., Devin, J., Szablewski, V., De Veirman, K., Menu, E., Moreaux, J., Vanderkerken, K. & De Bruyne, E., 18 nov 2019, In: Blood Cancer Journal. 9, 12, 11 blz., 87.Onderzoeksoutput: Article › peer review
Open AccessBestand10 Citaten (Scopus)17 Downloads (Pure) -
Myeloid-derived suppressor cells induce multiple myeloma cell survival by activating the AMPK pathway
De Veirman, K., Menu, E., Maes, K., De Beule, N., De Smedt, E., Maes, A., Vlummens, P., Fostier, K., Kassambara, A., Moreaux, J., Van Ginderachter, J. A., De Bruyne, E., Vanderkerken, K. & Van Valckenborgh, E., 1 feb 2019, In: Cancer Letters. 442, blz. 233-241 9 blz.Onderzoeksoutput: Article › peer review
51 Citaten (Scopus) -
Targeting of the histone methyltransferases G9a and GLP in multiple myeloma
De Smedt, E., Devin, J., Liu, H., Vlummens, P., Maes, K., Maes, A., De Veirman, K., Menu, E., Vanderkerken, K., Moreaux, J. & De Bruyne, E., 2019, In: Belgian Journal of Hematology. blz. 52-52 1 blz., PP17.Onderzoeksoutput: Meeting abstract (Journal)
-
TARGETING PROTEIN ARGININE METHYLTRANFERASE 5 (PRMT5) IN HIGH-RISK MULTIPLE MYELOMA: A NEW TREATMENT STRATEGY?
Vlummens, P., De Veirman, K., Menu, E., Vanderkerken, K., De Bruyne, E. & Maes, K., feb 2019, blz. PP13 - 49.Onderzoeksoutput: Poster
-
The anaphase-promoting complex/cyclosome: a new promising target in diffuse large B-cell lymphoma and mantle cell lymphoma
Maes, A., Maes, K., De Raeve, H., De Smedt, E., Vlummens, P., Szablewski, V., Devin, J., Faict, S., De Veirman, K., Menu, E., Offner, F., Spaargaren, M., Moreaux, J., Vanderkerken, K., Van Valckenborgh, E. & De Bruyne, E., 11 jun 2019, In: British Journal of Cancer. 120, 12, blz. 1137-1146 10 blz.Onderzoeksoutput: Article › peer review
Open AccessBestand12 Citaten (Scopus)14 Downloads (Pure) -
The Exosomal Transfer of Acid Sphingomyelinase Contributes to Drug Resistance in Multiple Myeloma
Oudaert, I., Faict, S., D'Auria, L., Dehairs, J., Maes, K., Vlummens, P., Jacobs, L., De Veirman, K., De Bruyne, E., Fostier, K., Vande Broek, I., Schots, R., Vanderkerken, K., Swinnen, J. V. & Menu, E., 13 nov 2019, In: Blood. 134, 1, blz. 1-3 3 blz., 3058.Onderzoeksoutput: Meeting abstract (Journal)
-
The Transfer of Sphingomyelinase Contributes to Drug Resistance in Multiple Myeloma
Faict, S., Oudaert, I., D'Auria, L., Dehairs, J., Maes, K., Vlummens, P., Veirman, K. D., Bruyne, E. D., Fostier, K., Broek, I. V., Schots, R., Vanderkerken, K., Swinnen, J. V. & Menu, E., 20 nov 2019, In: Cancers. 11, 12, 1823.Onderzoeksoutput: Article › peer review
Open AccessBestand45 Citaten (Scopus)36 Downloads (Pure) -
The Use of Murine Models for Studying Mechanistic Insights of Genomic Instability in Multiple Myeloma
Vlummens, P., De Veirman, K., Menu, E., De Bruyne, E., Offner, F., Vanderkerken, K. & Maes, K., 15 aug 2019, In: Frontiers in Genetics. 10, 11 blz., 740.Onderzoeksoutput: Scientific review › peer review
Open Access5 Citaten (Scopus) -
2018
Protein arginine methyltransferase PRMT5 in high-risk multiple myeloma : A possible new treatment strategy?
Vlummens, P., De Veirman, K., Menu, E., Vanderkerken, K., De Bruyne, E. & Maes, K., 2018, (Unpublished).Onderzoeksoutput: Poster
-
TARGETING PROTEIN ARGININE METHYLTRANFERASE PRMT5 IN HIGH-RISK MULTIPLE MYELOMA: A NEW TREATMENT STRATEGY?
Vlummens, P., De Veirman, K., Menu, E., Vanderkerken, K., De Bruyne, E. & Maes, K., nov 2018.Onderzoeksoutput: Poster
-
The genetic landscape of 5T models for multiple myeloma
Maes, K., Boeckx, B., Vlummens, P., De Veirman, K., Menu, E., Vanderkerken, K., Lambrechts, D. & De Bruyne, E., 1 dec 2018, In: Scientific Reports - Nature. 8, 1, 11 blz., 15030.Onderzoeksoutput: Article › peer review
Open AccessBestand17 Citaten (Scopus)16 Downloads (Pure)